Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin

BACKGROUND: Oral semaglutide was approved in 2019 for blood glucose control in patients with type 2 diabetes mellitus (T2DM) and was the first oral glucagon-like peptide 1 receptor agonist (GLP-1 RA). T2DM is associated with substantial healthcare expenditures in the US, so the cost of a new interve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoeconomics
Main Authors: Wehler, Elizabeth, Lautsch, Dominik, Kowal, Stacey, Davies, Glenn, Briggs, Andrew, Li, Qianyi, Rajpathak, Swapnil, Alsumali, Adnan
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2020
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7882575/
https://ncbi.nlm.nih.gov/pubmed/33150566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-020-00967-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados